Cancer Treatment Research Grants (Assistance Listing 93.395)

National Institutes of Health · Amount varies

This NIH HEAL Initiative UG3/UH3 cooperative agreement funds preclinical optimization and development of safe, non-addictive small-molecule and biologic therapeutics for treating pain, advancing candidates toward Phase II trials. Applicants must already have a promising lead candidate, a strong biological rationale, and established assays. Foreign organizations and foreign components of U.S. organizations are not eligible to apply.

National Institutes of Health · Up to $375K

This NIH R15 (REAP) award funds small-scale research and student research experiences at health-professional and graduate schools that receive limited NIH funding, with a minimal-risk clinical trial required. Eligibility is restricted to degree-granting institutions that have received no more than $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. Awards reach up to about $375,000. The NIH-funding cap and institution-type limits make eligibility narrow, so verify your institution qualifies.

National Institutes of Health · Amount varies

This NIH STTR program (R41/R42) funds U.S. small businesses that partner with a nonprofit research institution to move scientific innovations toward commercialization. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · Amount varies

This NIH SBIR Phase IIB award is restricted to U.S. small business concerns that have previously received an NIH SBIR or STTR Phase II award; it bridges the gap between Phase II and commercialization for later-stage R&D. Only one such award is allowed per project, and applications must be submitted within the first six due dates after the Phase II budget period ends, so it is narrow and limited to existing grantees. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH SBIR/STTR Commercialization Readiness Pilot (CRP) is restricted to U.S. small business concerns (as defined by the SBA) and helps move NIH-funded SBIR/STTR projects from late-stage development toward commercialization. It supports later-stage R&D and technical assistance such as replication studies, IND/IDE-enabling work, clinical studies, manufacturing scale-up, and regulatory support, and a significant portion may be subcontracted. Foreign organizations are not eligible to apply.

National Institutes of Health · Amount varies

This NIH/CDC/FDA SBIR program (R43/R44) funds U.S. small businesses developing scientific innovations toward commercial products through feasibility and R&D studies. Eligibility is limited to U.S. small business concerns as defined by the SBA, and foreign organizations are not eligible. No award amount is listed.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds the continued operation and maintenance of established, widely-adopted informatics tools and resources used across cancer research; clinical trials are optional. Applicants must demonstrate that their resource is already widely used and has had significant impact, so it targets teams maintaining existing informatics infrastructure rather than new projects. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · $50K–$600K

This NIH (NCI) U24 cooperative agreement funds advanced development and enhancement of emerging cancer informatics technologies that have passed initial prototyping but are not yet widely adopted; clinical trials are optional. It targets teams with a promising informatics tool ready for further development and broader impact, so eligibility is effectively oriented toward established research/informatics groups. Foreign organizations and the foreign components of U.S. organizations are eligible to apply, and foreign components are allowed. Awards range from about $50,000 to $600,000.

National Institutes of Health · Amount varies

This NIH/NCI program (UG1) funds NCORP Academic Community Sites, which are consortia led by an academic center with affiliated community hospitals and oncology practices, to broaden participation in cancer control, prevention, treatment, and care-delivery studies. Eligibility centers on academic medical centers with the infrastructure to support accrual across affiliates; foreign organizations and foreign components are not eligible. No award amount is stated. This is restricted to qualifying academic-led community research consortia, not general applicants.

National Institutes of Health · Amount varies

This NIH/NCI program (UG1) funds NCORP Community Sites, which are healthcare systems or consortia of community hospitals, oncology practices, public hospitals, or health centers that broaden participation in cancer control, prevention, treatment, and care-delivery research. Eligibility centers on healthcare systems and community-based oncology networks; foreign organizations and foreign components are not eligible. No award amount is stated. This is aimed at community healthcare organizations participating in NCORP, not individuals or general nonprofits.

National Institutes of Health · $50K–$300K

This NIH/NCI U01 funds early-stage development of informatics tools and technologies that improve how cancer research data is acquired, managed, analyzed, and shared. Eligibility is described in the funding notice, and foreign organizations and their U.S. components may apply. Awards run from about $50,000 up to $300,000. Projects must engage end users and show clear potential to advance cancer research, so the scope is specific.

National Institutes of Health · Amount varies

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH R61/R33 funds milestone-driven development of clinical trials to treat co-occurring health conditions in people with Down syndrome — up to two years of planning followed by up to three years of trial support. Clinical trials are required.

National Institutes of Health · Up to $500K

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH R01 funds groundbreaking, high-impact Down syndrome research across any relevant topic, with no preliminary data required. Awards up to about $500,000.

National Institutes of Health · Up to $200K

Open to U.S. and foreign research institutions, universities, nonprofits, and certain government/tribal organizations. This NIH R21 funds exploratory, higher-risk Down syndrome research — feasibility studies, novel methods, or new applications of existing techniques. Awards up to about $200,000.

National Institutes of Health · Up to $500K

This NIH (R01) Bioengineering Research Grant funds multidisciplinary projects that apply engineering approaches to biomedical, clinical, or translational problems, with a stated budget up to about $500,000. It supports clinical trials that validate performance but excludes Phase III trials, conventional non-translational trials, and commercial production. Eligibility is relatively broad for an NIH grant: both foreign organizations and foreign components of U.S. organizations are eligible to apply, though foreign components (as defined by NIH) are not allowed.

National Institutes of Health · Amount varies

This NIH opportunity provides administrative supplements only to organizations that already hold an active, eligible NIH grant or cooperative agreement, to cover unforeseen increased costs within the scope of the existing project. New applicants without a current NIH award cannot use it. Funding is not guaranteed, and applicants must discuss requests with the awarding Institute's staff before submitting; foreign organizations may apply only consistent with the existing parent award.

National Institutes of Health · Amount varies

For existing NCI early-stage-investigator MERIT (R37) awardees applying to extend their award, submitted through their U.S. or eligible institution. The extension provides up to seven years of total support across two segments, giving early-career cancer researchers extra time before a renewal. Eligibility is narrow — limited to current ESI MERIT grantees.

National Institutes of Health · Up to $499K

An NIH/NCI research project grant (R01, clinical trial not allowed) funding academic-industrial partnerships to translate scientific and engineering advances into tools for disease risk assessment, detection, diagnosis, and treatment. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. The award is capped at about $499,000. The partnership focus suits research institutions collaborating with industry rather than individuals.

National Institutes of Health · Up to $499K

An NIH/NCI research project grant (R01) funding academic-industrial partnerships to translate scientific and engineering advances into tools for disease risk assessment, detection, diagnosis, and treatment. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. The award is capped at about $499,000. The partnership focus suits research institutions collaborating with industry rather than individuals.

National Institutes of Health · Amount varies

The NIH parent Exploratory/Developmental Research Grant (R21, clinical trial required) supports early-stage research projects with at least one clinical trial, aligned with participating NIH institutes' missions. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. The clinical-trial requirement makes this best suited to research institutions with trial capacity.

National Institutes of Health · Amount varies

The NIH parent Exploratory/Developmental Research Grant (R21, clinical trial not allowed) supports early-stage, higher-risk research projects that may lead to breakthroughs or novel methods. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is an exploratory research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

The NIH parent Research Project Grant (R01, clinical trial not allowed) supports investigator-initiated research projects aligned with participating NIH institutes' missions, excluding clinical trials. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a core NIH research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

This NIH/NCI R01 funds advanced preclinical research translating nanotechnology-based cancer diagnostics and therapeutics toward later NCI translational programs; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Foreign organizations are not eligible. No award amount is specified, and the nanomedicine focus makes the scope narrow.

National Institutes of Health · Amount varies

An NIH/NCI exploratory/developmental bioengineering research grant (EBRG, R21, clinical trial not allowed) funding feasibility-stage projects that develop new capabilities or improvements for biomedical, pre-clinical, or clinical research and care. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a bioengineering research mechanism aimed at research institutions.

National Institutes of Health · Amount varies

An NIH/NCI exploratory/developmental bioengineering research grant (EBRG, R21, clinical trial optional) funding feasibility-stage projects that develop new capabilities or improvements for biomedical, pre-clinical, or clinical research and care. A broad range of domestic and foreign institutions may apply, including universities, tribal governments, and community-based organizations. No specific award amount is stated. This is a bioengineering research mechanism aimed at research institutions.

National Institutes of Health · Up to $375K

The REAP program funds small-scale research at health professional and graduate schools that haven't been major recipients of NIH support, while giving students hands-on research experience. Eligibility is limited to institutions awarding NIH-relevant degrees that received under $6 million per year in NIH support in 4 of the last 7 years — a specific financial threshold worth checking before applying. Awards go up to $375,000.

National Institutes of Health · Up to $375K

An NIH Academic Research Enhancement Award (AREA/R15) for undergraduate-focused institutions that do not receive substantial NIH funding, supporting small-scale biomedical research with undergraduate involvement. Eligibility is narrow: institutions must award baccalaureate science degrees and have received no more than about $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. The award is capped at about $375,000. This is restricted to qualifying lower-NIH-funded undergraduate institutions.

National Institutes of Health · Amount varies

This NIH AREA (R15) award funds small-scale research at undergraduate-focused institutions that receive limited NIH funding, emphasizing undergraduate research experiences; a minimal-risk clinical trial is required. Eligible institutions must grant baccalaureate science degrees and have received no more than about $6 million per year of NIH support in 4 of the last 7 years; foreign organizations are not eligible. No specific award amount is stated.

National Institutes of Health · Up to $500K

This NIH/National Cancer Institute R01 funds investigator-initiated early-phase (Phase 0, I, II) clinical trials for cancer diagnosis and treatment; a clinical trial is required. Eligible applicants include universities, research institutions, hospitals, tribal and community organizations, and foreign organizations. The maximum award is just under $500,000. It is geared toward established clinical research teams.

National Institutes of Health · Up to $500K

This NIH (R01) opportunity funds development and use of molecular imaging methods to study inflammation in cancer in vivo, encouraging collaboration between cancer biologists and imaging scientists. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $500,000.

National Institutes of Health · Up to $500K

An NIH/NCI research project grant (R01) funding projects that integrate medical imaging with fluid-based (liquid biopsy) tumor monitoring during cancer therapy. Eligible applicants are domestic institutions such as universities, tribal governments, and community-based organizations; foreign organizations and foreign components are not eligible. The award is capped at about $500,000. This is an oncology research mechanism aimed at research institutions, not individuals or general nonprofits.

National Institutes of Health · Amount varies

This NIH/National Cancer Institute R01 award supports assay development and screening to discover small-molecule chemical probes, drugs, or immunomodulators, with no clinical trials allowed. It is aimed at research institutions and investigators conducting early-stage discovery research, and lists a broad set of eligible U.S. organization types. Funding amounts are not specified here. Applications are submitted through eligible organizations.

National Institutes of Health · Up to $499K

This NIH/National Cancer Institute R01 award funds projects to improve the reliability and translational usefulness of mammalian cancer and tumor models, with no clinical trials allowed. It is aimed at research institutions and investigators, with a broad list of eligible U.S. organization types. The stated maximum award is about $499,000. Applications are submitted through eligible organizations rather than by individuals.

National Institutes of Health · Amount varies

This NIH (U01) program funds academic-industry research partnerships that develop and advance bioengineering tools and technologies to address biomedical problems, aiming for solutions deployable within roughly 5-10 years. Eligible applicants are research organizations including universities, colleges, government and tribal entities, and faith- or community-based organizations; it is geared toward multidisciplinary research teams partnered with industry, not individuals or general nonprofits. Award amounts are not specified. Applicants should expect a collaborative, milestone-driven structure.

National Institutes of Health · Up to $500K

This NIH/National Cancer Institute R01 funds academic-industrial partnerships to translate and validate in vivo imaging, data science, or spectroscopic technologies into tools for cancer and other diseases; a clinical trial is optional. Eligible applicants include universities, research institutions, and tribal and community organizations, and foreign organizations are listed among eligible applicants. The award maximum is about $500,000, and the model assumes an academic-industry collaboration. It is aimed at research teams.

National Institutes of Health · Amount varies

This NIH (R13) program supports conferences and scientific meetings relevant to public health and the missions of participating NIH institutes. Eligible applicants are U.S. research and education organizations including universities, government and tribal entities, and faith- or community-based organizations; foreign organizations and non-U.S. components are not eligible to apply, though some foreign components are allowed. Note that R13 conference support typically requires advance permission from the funding institute before applying. It is aimed at organizations hosting scientific conferences, not individuals. Award amounts are not specified.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific NIH grants and need to transfer an award due to a change in organizational status (successor-in-interest). It is an administrative prior-approval request, not a new funding opportunity, and approval of the transfer is not guaranteed. Only current NIH grantee organizations should use it; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Amount varies

This NIH mechanism is narrowly limited to organizations that already hold specific types of NIH grants and need to transfer an existing award to a new recipient institution (a change of recipient organization). It is an administrative prior-approval request, not a new funding opportunity, and there is no guarantee a transfer will be approved. Only current NIH grantee organizations should apply; it does not apply to individuals, new applicants, or general nonprofits. No award amount applies.

National Institutes of Health · Up to $375K

This NIH R15 (AREA) award supports small-scale research at undergraduate-focused institutions that receive limited NIH funding, with a required clinical trial. Eligibility is restricted to institutions that award baccalaureate science degrees and have received no more than $6 million/year of NIH support in 4 of the last 7 years; foreign organizations are not eligible to apply. The maximum award is about $375,000. This is narrowly targeted at less-research-intensive degree-granting institutions.

National Institutes of Health · Amount varies

This NIH P50 SPORE grant funds translational cancer research centers focused on improving prevention, early detection, diagnosis, and treatment for a specific organ system or related group of cancers. Projects must have a clear path toward a translational human endpoint within the grant period, and it's aimed at eligible U.S. research institutions. The deadline is September 25, 2026.